# Calidi Biotherapeutics Inc. (CLDI)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $1M  
**Price:** $0.17 (-3.26%)

> Calidi Biotherapeutics Inc. is a biotechnology company focused on developing innovative oncolytic virus-based immunotherapies for cancer treatment. Oncolytic viruses are engineered to selectively infect and destroy cancer cells while stimulating immunity against tumors. Calidi's primary goal is to harness the power of viral-based therapies to provide novel solutions for patients with unmet medical needs in oncology. The company is pioneering the development of combination therapies that integrate these oncolytic viruses with stem cell technology to enhance the delivery and efficacy of treatments. This approach positions Calidi Biotherapeutics as a key player within the biotech sector, impacting the broader healthcare and pharmaceutical industries. Established to spearhead advancements in cutting-edge cancer treatments, Calidi operates within a competitive yet rapidly growing market segment committed to improving patient outcomes and broadening the therapeutic landscape for cancer care. By capitalizing on advanced viral and cellular methodologies, Calidi Biotherapeutics aims to contribute significantly to the next generation of cancer therapies.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2022 | $45,000 | — | -$23M | -$25M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2022 | $3M | $43M | -$50M | — | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$21M | — | — |
| 2024 | -$20M | — | — |
| 2023 | -$27M | — | — |
| 2022 | -$13M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/CLDI)